MapLight Therapeutics Inc.
(NASDAQ:MPLT) reported mixed topline results from its Phase 2 IRIS study of ML-004 in patients with autism spectrum disorder.
The trial missed the trial's primary endpoint while demonstrating clinically meaningful improvements in irritability among a subgroup of adolescents. • MapLight Therapeutics stock is among today's top performers.
What's fueling MPLT momentum?
The findings, shared on Monday, could support further development of the drug in a more targeted patient population, reinforcing analysts' views that ML-004 may still hold significant commercial potential.
